At Norrsken Mind, we’re dedicated to advancing psychedelic science in Europe. We fund high-quality research and non-profit initiatives that explore the therapeutic potential of psychedelics and lay the foundation for the future integration of these treatments into healthcare.As a small, driven team of two, we’re looking for a COO to help implement our strategic vision and drive innovation in one of the most transformative fields in mental health today.
A comprehensive new report released today, funded by Norrsken Mind, maps the reimbursement landscape for psychedelic therapies across Europe, offering stakeholders an analytical look at the post-regulatory approval phase. While clinical research continues to highlight the therapeutic potential of psychedelics for conditions such as depression, PTSD, and addiction, this report zooms in on the critical challenge of securing sustainable market access and reimbursement.
Norrsken Mind is awarding eight grants totaling EUR 1.2 million (SEK 14 million) to support research and non-profit projects in psychedelic science. During this grant cycle, the Foundation is funding a clinical trial on psilocybin-assisted therapy for anorexia at Lund University, research at Karolinska Institutet and the University of Copenhagen on the psychotherapeutic component of psilocybin treatments, a report on reimbursement pathways in Europe for psychedelic therapy, and patient advocacy efforts.
The PsyPal consortium ("Consortium") is proud to announce that the clinical trial PsyPal has been authorised according to the Clinical Trials Regulation (CTR) in the participating member states, with conditions.
Norrsken Mind offers funding opportunities to European researchers and non-profit initiatives in psychedelic science. Applications for funding must address at least one of the foundation’s three focus areas: research, education and implementation.
Christina Rångemark Åkerman, former Director General of the Swedish Medical Products Agency, Carl Johan Fürst, Professor emeritus of palliative medicine at Lund University, and Mikael Horal, former Head of Fundraising at Karolinska Institutet, have been appointed as new board members.
The Interdisciplinary Conference on Psychedelic Research (ICPR) is returning for its sixth edition on June 6-8, 2024. In the day preceding ICPR on June 5, the Pathways to Access Summit (PATHS) convenes key stakeholders from Europe and beyond to explore the opportunities and challenges around the development, approval, and potential integration of psychedelic medicines into European health care.
The EU-funded PsyPal project, exploring the use of psilocybin in palliative care, will be launched at the European Parliament in Brussels on 9 April 2024 from 12:15 to 13:45. The launch event will offer a comprehensive overview of the project’s objectives and its potential impact on future mental health treatments.
%20(2).png)
%20(1920%20%C3%97%201080%20px)%20(2).png)
